Pharmaceuticals

Branded Generics Industry Insights: Market Forecast to 2029

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Branded Generics Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The branded generics market has seen substantial growth in its size over recent years. It is forecast to increase from $363.49 billion in 2024 to $393.5 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.3%. This historical expansion can be attributed to factors such as cost savings and affordability, patent expiries, broader market expansion and access, government initiatives and policies, and various healthcare reforms.

The branded generics market size is anticipated to experience rapid growth in the coming years, with projections indicating it will expand to $588.37 billion in 2029, achieving a compound annual growth rate (CAGR) of 10.6%. This growth during the forecast period can be attributed to the growing demand for generic biologics, rising chronic diseases, emerging markets growth, and a focus on biosimilars. Key trends identified for the forecast period include strategic partnerships and collaborations, technological advancements, a focus on chronic diseases, market consolidation, and a patient-centric approach.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

Which Drivers Are Impacting The Branded Generics Market?

The rising occurrence of chronic diseases is set to fuel the expansion of the branded generics market. These are persistent health conditions that, while often not fully curable, can be managed and controlled. Their growing incidence is linked to factors such as increased tobacco consumption, inadequate nutrition, lack of physical activity, and excessive alcohol intake, among others. Globally, consumers are increasingly choosing branded generics for the treatment of chronic conditions due to their affordability compared to standard medications. A clear example is from September 2022, where the World Health Organization (WHO) 2022 Highlights, provided by the Switzerland-based intergovernmental health organization, reported that noncommunicable diseases (NCDs), also known as chronic diseases, were responsible for 41 million deaths annually worldwide, accounting for 74% of all fatalities. Consequently, the rising prevalence of chronic diseases is anticipated to significantly elevate the demand for branded generics throughout the forecast period.

What Are The Different Segment Classifications Within The Branded Generics Market?

The branded generics market covered in this report is segmented –

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues

3) By Hormones: Corticosteroids, Thyroid Hormones

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers

5) By Lipid Lowering Drugs: Statins, Fibrates

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs

9) By Other Drugs: Analgesics, Antibiotics, Antivirals

Which Key Trends Are Expected To Influence The Branded Generics Market In The Coming Years?

A prominent trend in the branded generics market is strategic partnership, with companies in this sector collaborating with relevant firms to combine resources and venture into new markets. For instance, in September 2024, Biocon Ltd., an India-based pharmaceutical company, established a partnership with Tabuk Pharmaceuticals. Biocon will undertake the development and manufacturing of GLP-1 products, ensuring the creation of high-quality biopharmaceuticals tailored for diabetes treatment. Tabuk Pharmaceuticals will possess the marketing authorization rights and will oversee the registration, importation, and promotion of these products across the Middle East, particularly within Saudi Arabia. The agreement also contains provisions for future expansion into other GLP products beyond the initial offerings, enabling a broader array of diabetes treatments. This partnership aims to deliver unique health solutions that enhance the well-being of patients in Saudi Arabia and surrounding areas, aligning with both companies’ commitment to improving healthcare access. Tabuk Pharmaceuticals is a Saudi Arabia-based pharmaceutical company that markets both branded and generic pharmaceutical products.

Which Key Market Players Are Investing In Expansion And Innovation Of Branded Generics Market?

Major companies operating in the branded generics market include Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

How Does The Branded Generics Market Perform Across Key Geographic Regions?

North America was the largest region in the branded generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Branded Generics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=7186&type=smp

Browse Through More Reports Similar to the Global Branded Generics Market 2025, By The Business Research Company

Gastrointestinal Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Nutritional Feed Additives Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nutritional-feed-additives-global-market-report

Pharmacies And Drug Stores Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmacies-and-drug-stores-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795